Effects of plasmapheresis on peripheral blood mononuclear cell populations from patients with macroglobulinemia
โ Scribed by Teresa Paglieroni; Vincent Caggiano; Malcolm R. Mackenzie
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 597 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
โฆ Synopsis
Effects of plasrnapheresis on peripheral blood T-cell. B-cell, monocyte, and natural-killer-cell populations were studied in ten macroglobulinemia patients with hyperviscosity syndrome. Following plasrnapheresis, there was a transient decrease in the number of T4+ helper cells and a longer-lasting decrease in the number of Leu-7+ natural killer cells and Mo2+ monocytes. In addition, there was a greater than 50% decrease in the in vitro ingestion capacity of monocytes. Although no significant changes in the numbers of IgM+, BI+, B4+, or PCA+ B cells (P > -05) were detected, there was a highly significant (P < .01) increase in 12 antigen density on the surface of IgM + B cells and in the bromodeoxyuridine uptake by these cells 7-9 days after plasmapheresis. These findings suggest that following plasrnapheresis, IgM + B cells are activated. Using flow cytonietry to determine when maximum IgM + B cell activation occurs by measuring I2 antigen density on the cell surface may be useful in determining the postplasmapheresis timing of chemotherapy in macroglobulinemia patients with hyperviscosity syndrome who require more aggressive treatment.
๐ SIMILAR VOLUMES
## Abstract The effect of human interferon (IFN) preparations on the metabolic pathway leading to the synthesis of phosphatidylcholine (PC) by a stepwise addition of methyl groups to phosphatidylethanolamine (PE) was investigated in human peripheral blood mononuclear (PBMN) cells. An inhibition of
We studied the binding of ""I-labeled human interferon-a to peripheral blood mononuclear cells and the activity of 2',5'-oligoadenylate synthetase in peripheral blood mononuclear cells obtained from 2 l patients with chronic hepatitis B who were treated with human interferon-a or interferon+. Fourte